Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,901-1,950 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_B4,16 | Lung | Primary cancer | 1,578 | Stromal | 26.7% | 0.81 | 0.49 |
| NSCLC_38242124__IMC__88_B4,2 | Lung | Primary cancer | 2,795 | Tumor/Malignant | 44.5% | 0.91 | 0.32 |
| NSCLC_38242124__IMC__88_B4,3 | Lung | Primary cancer | 4,121 | Stromal | 26.2% | 0.85 | 0.36 |
| NSCLC_38242124__IMC__88_B4,4 | Lung | Primary cancer | 5,116 | Stromal | 59.5% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_B4,5 | Lung | Primary cancer | 3,705 | Tumor/Malignant | 34.6% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__88_B4,6 | Lung | Primary cancer | 5,898 | Immune | 81.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_B4,7 | Lung | Primary cancer | 2,710 | Stromal | 30.1% | 0.87 | 0.38 |
| NSCLC_38242124__IMC__88_B4,8 | Lung | Primary cancer | 2,611 | Immune | 33.5% | 0.89 | 0.36 |
| NSCLC_38242124__IMC__88_B4,9 | Lung | Primary cancer | 483 | Tumor/Malignant | 36.4% | 0.91 | 0.22 |
| NSCLC_38242124__IMC__88_B5,1 | Lung | Primary cancer | 3,360 | Tumor/Malignant | 29.6% | 0.91 | 0.30 |
| NSCLC_38242124__IMC__88_B5,10 | Lung | Primary cancer | 2,455 | Tumor/Malignant | 48.4% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__88_B5,11 | Lung | Primary cancer | 2,235 | Tumor/Malignant | 44.3% | 0.48 | 0.75 |
| NSCLC_38242124__IMC__88_B5,12 | Lung | Primary cancer | 3,349 | Other | 28.9% | 0.41 | 0.97 |
| NSCLC_38242124__IMC__88_B5,13 | Lung | Primary cancer | 2,743 | Stromal | 28.2% | 0.67 | 0.75 |
| NSCLC_38242124__IMC__88_B5,14 | Lung | Primary cancer | 2,532 | Tumor/Malignant | 47.4% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__88_B5,15 | Lung | Primary cancer | 3,873 | Tumor/Malignant | 28.1% | 0.90 | 0.34 |
| NSCLC_38242124__IMC__88_B5,16 | Lung | Primary cancer | 3,905 | Tumor/Malignant | 66.4% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__88_B5,2 | Lung | Primary cancer | 2,901 | Tumor/Malignant | 58.3% | 0.94 | 0.23 |
| NSCLC_38242124__IMC__88_B5,3 | Lung | Primary cancer | 1,956 | Tumor/Malignant | 51.5% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__88_B5,4 | Lung | Primary cancer | 2,354 | Tumor/Malignant | 58.3% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__88_B5,5 | Lung | Primary cancer | 4,378 | Tumor/Malignant | 79.3% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_B5,6 | Lung | Primary cancer | 2,423 | Tumor/Malignant | 28.5% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__88_B5,7 | Lung | Primary cancer | 232 | Immune | 70.7% | 0.37 | 0.82 |
| NSCLC_38242124__IMC__88_B6,1 | Lung | Primary cancer | 3,161 | Tumor/Malignant | 28.0% | 0.52 | 0.90 |
| NSCLC_38242124__IMC__88_B6,10 | Lung | Primary cancer | 1,414 | Tumor/Malignant | 82.3% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__88_B6,12 | Lung | Primary cancer | 1,589 | Other | 39.8% | 0.37 | 0.95 |
| NSCLC_38242124__IMC__88_B6,14 | Lung | Primary cancer | 2,851 | Tumor/Malignant | 34.2% | 0.49 | 0.88 |
| NSCLC_38242124__IMC__88_B6,15 | Lung | Primary cancer | 3,265 | Stromal | 26.7% | 0.83 | 0.47 |
| NSCLC_38242124__IMC__88_B6,16 | Lung | Primary cancer | 3,196 | Tumor/Malignant | 77.2% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_B6,2 | Lung | Primary cancer | 2,660 | Tumor/Malignant | 51.8% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__88_B6,3 | Lung | Primary cancer | 2,411 | Tumor/Malignant | 48.7% | 0.93 | 0.20 |
| NSCLC_38242124__IMC__88_B6,4 | Lung | Primary cancer | 3,055 | Tumor/Malignant | 35.2% | 0.45 | 0.77 |
| NSCLC_38242124__IMC__88_B6,5 | Lung | Primary cancer | 4,509 | Tumor/Malignant | 82.6% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_B6,6 | Lung | Primary cancer | 1,875 | Tumor/Malignant | 68.2% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_B6,7 | Lung | Primary cancer | 2,103 | Tumor/Malignant | 68.0% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_B6,8 | Lung | Primary cancer | 2,661 | Tumor/Malignant | 44.7% | 0.90 | 0.33 |
| NSCLC_38242124__IMC__88_B6,9 | Lung | Primary cancer | 2,809 | Tumor/Malignant | 40.6% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__88_B7,1 | Lung | Primary cancer | 1,493 | Tumor/Malignant | 60.5% | 0.89 | 0.27 |
| NSCLC_38242124__IMC__88_B7,10 | Lung | Primary cancer | 3,431 | Tumor/Malignant | 76.7% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_B7,11 | Lung | Primary cancer | 4,633 | Tumor/Malignant | 90.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_B7,12 | Lung | Primary cancer | 2,647 | Stromal | 30.6% | 0.58 | 0.83 |
| NSCLC_38242124__IMC__88_B7,13 | Lung | Primary cancer | 4,755 | Tumor/Malignant | 62.2% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_B7,14 | Lung | Primary cancer | 284 | Other | 60.2% | 0.81 | 0.44 |
| NSCLC_38242124__IMC__88_B7,16 | Lung | Primary cancer | 844 | Tumor/Malignant | 33.8% | 0.71 | 0.62 |
| NSCLC_38242124__IMC__88_B7,2 | Lung | Primary cancer | 1,854 | Stromal | 47.4% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__88_B7,3 | Lung | Primary cancer | 4,192 | Immune | 31.8% | 0.46 | 0.81 |
| NSCLC_38242124__IMC__88_B7,4 | Lung | Primary cancer | 460 | Tumor/Malignant | 67.2% | 0.94 | 0.15 |
| NSCLC_38242124__IMC__88_B7,5 | Lung | Primary cancer | 5,248 | Tumor/Malignant | 66.0% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__88_B7,6 | Lung | Primary cancer | 3,607 | Tumor/Malignant | 71.9% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_B7,7 | Lung | Primary cancer | 3,116 | Immune | 63.1% | 0.96 | 0.12 |